Teva Pravachol Exclusivity Loss Raises Bristol’s Stakes For Switch
This article was originally published in The Tan Sheet
Executive Summary
Bristol-Myers Squibb has more to gain from an Rx-to-OTC switch of the cholesterol-lowering drug Pravachol (pravastatin) if an FDA decision allowing multiple generics on the market in April 2006 is upheld
You may also be interested in...
Teva Entitled To Exclusivity Period For Generic Pravachol – D.C. Court
Teva's 180-day marketing exclusivity period for its generic equivalent of Bristol-Myers Squibb's Rx Pravachol (pravastatin) has "neither expired nor even commenced," District of Columbia District Court ruled Oct. 21
Bayer Stake In OTC Pravachol Could Influence Bristol OTC Unit Divestiture
Bayer could have a financial interest in Bristol-Myers Squibb's consumer franchise due to its Pravachol OTC marketing agreement regardless of whether it purchases the unit
Pravachol OTC Deal Reached Between Bayer, Bristol
Bayer is following through on its aim to become the preeminent switch player through a deal with Bristol-Myers Squibb for OTC Pravachol in the U.S